Product Description
MT027, an allogeneic chimeric antigen receptor T-cell (UCAR-T) therapy targeting B7-H3, is prepared using T cells from healthy donors. As a next-generation off-the-shelf CAR-T product, MT027 can be immediately and readily available for patients, addressing the common challenges of autologous cell therapies such as lengthy preparation cycles, insufficient capacity, and patients’ T cells not meeting the manufacturing criteria, which often result in many patients unable to receive CAR-T therapy timely. Additionally, the expected medical costs are significantly reduced, relieving patients’ financial burden. (Sourced from: https://advancedtherapies.com/t-maximum-car-t-strategic-partnership/)
Mechanisms of Action: CAR-T,B7-H3
Novel Mechanism: Yes
Modality: CAR-T
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: T-MAXIMUM
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 4
Highest Development Phases
Phase 1: Brain Stem Cancer|Central Nervous System Cancer|Glioma|Mesothelioma|Peritoneal Cancer|Pleural Effusion, Malignant
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| MT027-PNT-001 | P1 |
Recruiting |
Peritoneal Cancer |
2028-10-31 |
|
| MT027-HGG-002 | P1 |
Not yet recruiting |
Glioma |
2026-06-30 |
|
| MT027-MPE-001 | P1 |
Recruiting |
Mesothelioma|Pleural Effusion, Malignant |
2026-05-01 |
|
| MT027-BSM-001 | P1 |
Not yet recruiting |
Central Nervous System Cancer|Brain Stem Cancer |
2025-12-30 |